Abstract
110P - Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1093/annonc/mdx654.018
Copy DOIJournal: Annals of Oncology | Publication Date: Nov 1, 2017 |
License type: elsevier-specific: oa user license |
110P - Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.